Fulvestrant

Catalog No.S1191 Synonyms: ICI-182780, ZD 9238

Fulvestrant Chemical Structure

Molecular Weight(MW): 606.77

Fulvestrant is an estrogen receptor (ER) antagonist with IC50 of 0.94 nM in a cell-free assay.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 270 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • PTPH1 confers breast cancer cell sensitivity to fulvestrant. E and F, PTPH1 overexpression increases the growth inhibition by fulvestrant. PTPH1 was overexpressed by a Tet-on system or a stable transfection, and resultant cells were incubated with fulvestrant as indicated for about 2 weeks. Colony formed was stained and counted. Results shown are normalized to its own solvent control of Vector and PTPH1-overexpressed cells, respectively (means ± SD; n = 3–5) with insets showing PTPH1 overexpression. *, versus vector or no Tet cells for E and F.

    Mol Cancer Ther 2014 13(1), 230-8. Fulvestrant purchased from Selleck.

     

    Fulvestrant resistance induced by 6 different ZF-TFs. (A) Drug sensitivity of fulvestrant-selected MCF7 ZF-TF-transduced cells. MCF7 cells transduced with one of six different ZF-TF-expressing retroviruses selected first in puromycin (the transduction selection marker) and then in fulvestrant for 1 month were grown in the absence of fulvestrant for 7 days and then challenged with 100 nM fulvestrant or vehicle (0.1% ethanol) for 21 days followed by crystal violet staining and visualization. Data are representative of triplicate experiments.

    PLoS One 2011 6, e21112. Fulvestrant purchased from Selleck.

  • Fulvestrant resistance induced by 6 different ZF-TFs. (B and C) Growth curves of MCF7 and T47D cells in the presence and absence of fulvestrant. Comparison of cell growth rates (cell number, mean +/2 SEM, n = 8; time in days as indicated) of MCF7 and T47D cells stably transduced with control retrovirus or one of six different ZF-TF-expressing retroviruses (7, 19, 64, 70, 83 and 115) in the presence (blue line) or absence (pink line) of fulvestrant.

    PLoS One 2011 6, e21112. Fulvestrant purchased from Selleck.

Purity & Quality Control

Choose Selective Estrogen/progestogen Receptor Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Fulvestrant is an estrogen receptor (ER) antagonist with IC50 of 0.94 nM in a cell-free assay.
Targets
ER [1]
(Cell-free assay)
0.94 nM
In vitro

Fulvestrant is an effective inhibitor of the growth of ER-positive MCF-7 (with IC50 of 0.29 nM) but with no effect on the growth of ER-negative BT-20 human breast cancer cells. Fulvestrant causes accumulation of cells in G0/G1 and also reduces the proportion of cells capable of continued DNA synthesis. [1] Fulvestrant competitively inhibits binding of oestradiol to the estrogen receptor. Fulvestrant blocks nuclear localization of the ER through impairing receptor dimerisation, and energy-dependent nucleo-cytoplasmic shuttling. Because of the instability of fulvestrant-ER complex, the binding of Fulvestrant with ER finally results in accelerated degradation of the ER protein. [2] Fulvestrant (10 nM) not only decreases IGF-IR mRNA levels but also decreases the half-life. [3] Treatment with 100 μM Fulvestrant leads to a time dependent increase of TNFR1 and TRADD steady-state mRNA levels in MCF-7 cells. [4] Fulvestrant is capable of down-regulating androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. Fulvestrant also significantly attenuates R1881-stimulated growth by 70%. [5] Fulvestrant is able to modulate mitosis and cell death in immature cerebellar neurons via rapid activation of MAPK. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 NIe0Rm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHf3NGEyNjNvMUCwNEBvVQ>? NF;MdY41QCCq NHToT4RqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NHGwNYEzPDl5OUK5OC=>
MCF-7/LTED M4fNUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUmxMlMuOTByMDDuUS=> M4fObVQ5KGh? NHzqeHZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MYOyOFk4QTJ7NB?=
HCC1428 MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmj3NU4{NTFyMECgcm0> NHXhN|M1QCCq MlnCbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NYPxOmJPOjR7N{myPVQ>
HCC1428/LTED M{fRUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvjO5BtOS5|LUGwNFAhdk1? M37M[lQ5KGh? NVXnfmNncW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1r2dVI1QTd7Mkm0
LCC1 NXf3XWRwTnWwY4Tpc44hSXO|YYm= NYXqTGtmOTByIH7N MoS5OFguOTR2IHi= NH;5cFRi[3SrdnH0[ZMhXVCUIIPp[45idGmwZx?= MYGyOFg2QDJ5Nx?=
LCC9 NX7kR21oTnWwY4Tpc44hSXO|YYm= NU\FWVlvOTByIH7N NIfl[XU1QC1zNESgbC=> NGfIdm1i[3SrdnH0[ZMhXVCUIIPp[45idGmwZx?= MnPBNlQ5PTh{N{e=
MCF-7  NH[0SYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHzNVAxKG6P M2[4S|Uh\A>? M1PCZYlvcGmkaYTzJINmdGxiZ4Lve5RpKHSxIEGw89yG NU[1[nVYOjR6MUm1OVA>
mesangial  M4rDXWZ2dmO2aX;uJGF{e2G7 M3HTflAvOS1zMECgcm0> M1K1U|Q5KGh? MknLd5VxeHKnc4Pld{BVT0ZvzsKxMYlv\HWlZXSgeJlx\SCLVjDjc4xt[Wenbh?= MWSyOFc6OzZ|OR?=
Mesangial MnnZSpVv[3Srb36gRZN{[Xl? MWCwMlEuOTByIH7N NVX4eJcyOC53IHi= M3XYd4lvcGmkaYTzJHRITi4QskGtbY5lfWOnZDDTcYFlOiCyaH;zdIhwenmuYYTpc44hfmmjIFfQSXI> Mkj1NlQ4QTN4M{m=
ER+ MCF-7/2a MkHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYi3O2xsUUN3ME2wMlAxPCEQvF2= Ml3jNVU{OjR6OES=
ER+ MCF-7 NHrxUnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXJTZgzODBiaB?= MoHQTWM2OD1yLkKxJI5O NHrXdFMyPTN{NEi4OC=>
MCF-7  M3nFfGZ2dmO2aX;uJGF{e2G7 Mmr6NVDDqG6PwrC= NVPBUnVYPzJiaB?= NVnFPWV1emW4ZYLz[ZMhfGinIHXzeJJw\2WwIHXm[oVkfCiLQ{WwJFEvQSEFlzCxNQKJmjliTTm= MVeyOFkxQDZ3Mh?=
MCF-7  NEXOO2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrLOVVKSzVywrDv[kBieHC{b4jpcYF1\Wy7IEKgcm0> MX2yN|Q1QDN2Nh?=
H1975  M4izOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorVN:Kh|ryP M3m5PFEhdQ>? M2jndIlv[3KnYYPld{B1cGViZ3XmbZRqdmmkIIPlcpNqfGm4aYT5JI9nKEhzOUe1JINmdGy|wrC= NH[4emkzPDJ4OEixNC=>
H1975 M124dWZ2dmO2aX;uJGF{e2G7 NHTuO3M{yqEQvF2= MUexJI0> NWfkbFNJfXC{ZXf1cIF1\XNidHjlJIxmfmWuIH;mJGxmfC15Yx?= M1\0PVI1OjZ6OEGw
MCF-7  M1TheWZ2dmO2aX;uJGF{e2G7 MUWxNFDjiImwTdMg NGrN[pE4OiCq M4O0[5JmfmW{c3XzJJRp\SCycn;0[YN1cX[nIHXm[oVkfCCxZjDFNuKhcW5iY3XscEBqdn[jc3nvci=> M4fwWFI{QTN4N{ez
MCF-7  MojUSpVv[3Srb36gRZN{[Xl? MlfuNVAx6oDLbl5CpC=> NYXwbGFDOjRxNEigbC=> MVTmZYNqdGm2YYTld{Bqdn[jc3nvckB1cHKxdXfoJG1OWHNpIH3v[JVt[XSrb36= MWSyN|k{Pjd5Mx?=
BT474-tet-shMED1 M2rUe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfNc5gxNjFvNTFOwG0> M4nne|ch\A>? MU\pcoNz\WG|ZYOgL2RwgCCrbnT1Z4VlKGOnbHyg[IVifGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1jXR|I{QTN4MkO0
ZR75-1-tet-shMED1  NF7vd5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPidGk2OC5zLUWg{txO MXm3JIQ> NU\o[HFJcW6lcnXhd4V{KCuGb4igbY5lfWOnZDDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MmT6NlM6OzZ{M{S=
MCF-7-tet-shMED1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LidFAvOS13IN88US=> MWO3JIQ> Mo\kbY5kemWjc3XzJEtFd3hiaX7keYNm\CClZXzsJIRm[XSqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M1rmd|I{QTN4MkO0
HepG2  NEPmVmRHfW6ldHnvckBCe3OjeR?= NWfDN5h{OC5yMT2xNEDPxE1? MlnLNVghcMLi NE\hRmhi[3SrdnH0[ZMhfGinIFXSSU1u\WSrYYTl[EB1emGwc3PybZB1cW:wIH;mJGFHOkWU M3HDOVI{PzN|MUi4
MCF-7L  NFvwZpVHfW6ldHnvckBCe3OjeR?= NHjPW4cyODBibl5CpC=> M3fXUlExKG2rbj:yOEBpNzR6IHi= MUTy[ZN2dHS|IHnuJGVITlJuIFjFVlIh[W6mIFjFVlMheGixc4Doc5J6dGG2aX;uJIF1KHC{b3zvcodm\CCneIDvd5Vz\Q>? NEj4Vo0zOzZ6NkSxOi=>
MCF-7L  MoXPSpVv[3Srb36gRZN{[Xl? NV31dJpuOTByIH7NxsA> NGfTSVk1QCCq NHLZb|NqdmS3Y3XzJJVxemWpdXzheIlwdiCxZjDtVm5CKG:oIFXHSnIhdGmpYX7kJGhDNUWJRh?= NGnKUpMzOzZ6NkSxOi=>
MCF-7L MlPCSpVv[3Srb36gRZN{[Xl? NYTte3pPOTByIH7NxsA> MUm0PEBp M4XFbYlv\HWlZYOgSWdHWiCoYX3pcJkhdWWvYnXyJIFkfGm4YYTpc44hemWzdXny[YQhTVJ? M1TZbVI{Pjh4NEG2
C4-12  NVHyb4xjTnWwY4Tpc44hSXO|YYm= NFLnXVkyODBibl5CpC=> NX\1c4J{PDhiaB?= MWXpcoR2[2W|IFXHSnIh\mGvaXz5JI1mdWKncjDhZ5RqfmG2aX;uJJJmeXWrcnXkJGVT NIHYUlYzOzZ6NkSxOi=>
MCF-7L MmjtSpVv[3Srb36gRZN{[Xl? M2roTVExOCCwTdMg M2fHXlI1KGh? NHX1dFdqdmS3Y3XzJGVITlJicHjvd5Bpd3K7bHH0bY9vKHKncYXpdoVlKEiELVXHSkBnfW6ldHnvci=> M37N[|I{Pjh4NEG2
MMQ  M4naXGZ2dmO2aX;uJGF{e2G7 NEPMc5AxNTZ{NTDuUS=> M{e2[lczKGh? MmOz[I94di2{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiZYP0do9o\W5icnXj[ZB1d3JvzsGgLGVT|rFr MYGyN|UzOzN3Nx?=
H1975  MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPqNE4{OTJ3LUGwJO69VQ>? MVK2JIQ> NYjyN2ZIcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MmHhNlM{QTl7NUe=
H1975  NUD1PXluSXCxcITvd4l{KEG|c3H5 NGLhO3czODBibl2= MknvO|IhcA>? NYW2cYFP\W6qYX7j[ZMh\XKub4TpcoljKGmwZIXj[YQh[XCxcITvd4l{ M2\Q[|I{Ozl7OUW3
MCF-7  NVPnNZZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvX[YlKOTBxMUCwM|ExODBibl2= M2fmOVIwPC94IHS= M{HEfmROW09? MmP1bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEBld3OnLTDhcoQhfGmvZT2g[IVx\W6mZX70JI1idm6nch?= MmDxNlM{OTN3ME[=
MCF-7  MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTENVAxKG6P MkDmOEBl Mn;DSG1UVw>? M4DZfYlv\HWlZYOgZUBpcWeqZYKgdJJweG:{dHnvckBw\iClZXzsd{BqdiC2aHWgS|EheGijc3ZCpC=> M3fsZ|I{OzF|NUC2
MLO-Y4  NG\DWmdHfW6ldHnvckBCe3OjeR?= MoLsNeKh|ryP MV6xJIg> NFvacXhqdmirYnn0d{BGOi2rbnT1Z4VlKEO6NEOg[ZhxemW|c3nvci=> M1;rT|I{OjR5MEW3
MCF-7 NYTBcWMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;TZ5RpOTByIH7N MlO0OFghcA>? MnHFZYJzd2ejdHXzJJRp\SCycn;sbYZmemG2aY\lJIVn\mWldDDv[kBud2SncnH0[UBvcXS{b4PheIl3\SC|dILld5M> MVyyN|IyPjd2NB?=
TG1-1  M3\6cWZ2dmO2aX;uJGF{e2G7 NF;aWWQyyqEQvF2= M4j6XFI1KGh? NVXSeWtE[WK{b3fheIV{KEV{wrDpcoR2[2WmIHHjZ5VufWyjdHnvckBw\iCKSV[tNe6y M4DLPFI{ODh6NkC3
TG1-1  MnXESpVv[3Srb36gRZN{[Xl? M1W0XVHDqM7:TR?= NIPmW3YzPCCq M1v1UYFjem:pYYTld{BGOsLiaX7keYNm\CCjY3P1cZVt[XSrb36gc4YhWEl|Sx?= M1rhTVI{ODh6NkC3
MCF7 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWqxNFAhdk1? NGnpSHA1QCCq MVns[YFleyC2bzDhJJNqdWmuYYKgcI9{eyCrbjDzeZJ3cX[jbDDhd{B4cXSqIHTvfI9zfWKrY3nuJIFtd26n MnO1NlMxPzd{NEm=
MCF7 NVjlSHZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYmxNFAhdk1? NWnGd3Q{PDhiaB?= NGnTcXhmdmijbnPld{BvfXSuaX6tcYVlcWG2ZXSgZ4VtdCCmZXH0bC=> MVWyN|A4PzJ2OR?=
MCF-7  NVPsO4d3TnWwY4Tpc44hSXO|YYm= NH;XPIM3KGh? NH3XbHlFVVOR MoHoZZR1\W63YYTld{B1cGViZnz1[IlwgG:waXytJI9zKG[nbnjlfIFucWRvaX7keYNm\CCrbnPy[YF{\SCrbjDtbXIuOjFiZYjwdoV{e2mxbh?= M{XjZ|I{ODV{MEO2
MCF-7 NYHJOVZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYK1THdkOTByIH7NM|Eh|ryP M1\UcVUh\A>? NWPPOHg{cW6qaXLpeJMhfGinIIP0bY12dGG2aX;uJI9nKDF5zsKt[ZN1emGmaX;s NWW3dmdnOjJ7OEK3OlU>
MCF-7 NYLUdW9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjkdoIyODBibl2= Ml3YOUBl MU\pcohq[mm2czD0bIUhe3SrbYXsZZRqd25ib3[g[pV{[XKrZXzpckBJ MlzqNlI6QDJ5NkW=
1471.1 NX\WOI06TnWwY4Tpc44hSXO|YYm= M4\DVlExOCCwTR?= MnP2NUBp MkTwSZRQUMLi MYH0ZYtmeyCxbjDhJJB2dmO2YYTlJJN1[WmwaX7nJJBifHSncn6= MoXHNlI5PjlzME[=
MCF-7 M2jvemZ2dmO2aX;uJGF{e2G7 MlfKNVAxKG6P NFfCeGYyKGh? MnrSSZRQUMLi NEm0PWt1[WunczDvckBiKHC3bnP0ZZRmKHO2YXnubY5oKHCjdITldo4> NILQNXkzOjh4OUGwOi=>
HeLa NID4eWNHfW6ldHnvckBCe3OjeR?= MU[xNFAhdk1? MYGxJIg> MXvFeG9JyqB? MX\0ZYtmeyCxbjDhJJB2dmO2YYTlJJN1[WmwaX7nJJBifHSncn6= MWKyNlg3QTFyNh?=
COS-7  M2X2d2Z2dmO2aX;uJGF{e2G7 NXrXcXFDOTByIH7N MonjNUBp MWDFeG9JyqB? M3u4TJRic2W|IH;uJIEheHWwY4TheIUhe3SjaX7pcocheGG2dHXyci=> MoHyNlI5PjlzME[=
BG1L-OHTLT  NYLhTZM6TnWwY4Tpc44hSXO|YYm= MV:xNOKhdk1? M4LuZ|I1yqCqwrC= MkDpbY5pcWKrdIOgSXLPuSCneIDy[ZN{cW:w M37rV|IzPjV{NUW4
BG1L-ICILT MXvGeY5kfGmxbjDBd5NigQ>? M3ntclExyqCwTR?= NH33Vm0zPMLiaNMg M4TGU4lvcGmkaYTzJGVT|rFiZYjwdoV{e2mxbh?= MUOyNlY2OjV3OB?=
PC-9 M2fDfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUWwMlAxOy1|MDFOwG0> MYm0PEBp M1fPS4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NFvn[24zOjV4ME[zOC=>
H1650 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rtUlAvODB|LUOwJO69VQ>? M13vZVQ5KGh? NITrNoFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NVraeoFqOjJ3NkC2N|Q>
H1975 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoOwNE4xODNvM{Cg{txO MlnEOFghcA>? NXzBcXdvcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NVflOZlnOjJ3NkC2N|Q>
H1975 MlGySpVv[3Srb36gRZN{[Xl? MlmyN:Kh|ryP NUWxTlh7OyCq MX\hZpJw\2G2ZYOgeIhmKHCqb4PwbI8uTUeIUjDpcoR2[3Srb36gZpkh\XO2cn;n[Y4> M4\HdVIzPTZyNkO0
H1975 MXLGeY5kfGmxbjDBd5NigQ>? NVLrV|VjO8LizszN M3;WTlch\A>? M1yxSIlv\HWlZYOgSWdHWiCneIDy[ZN{cW:w M2DMWVIzPTZyNkO0
HTR-8 NEn2NVNHfW6ldHnvckBCe3OjeR?= MXixxsDPxE1? MonUNU01QCCq M332[IRwf25vcnXneYxifGW|IITo[UBmgHC{ZYPzbY9vKG:oIFnHSmJRPyCvUl7B NHXodlEzOjN6M{GxNS=>
JEG-3 MXLGeY5kfGmxbjDBd5NigQ>? MWCxxsDPxE1? NUHlVIJuOS12ODDo M3y4bYRwf25vcnXneYxifGW|IITo[UBmgHC{ZYPzbY9vKG:oIFnHSmJRPyCvUl7B MmDxNlI{QDNzMUG=
Huh7 MXXGeY5kfGmxbjDBd5NigQ>? M37UflUxyqEQvF2= NWfpTWlFPDhiaB?= M1r2e4lvcGmkaYTzJIdmdmm|dHXpck1u\WSrYYTl[EBRV05zIITyZY5{[WO2aY\heIlwdg>? NInBNmIzOjNyNEK5Oi=>
201T M2Xm[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3nZW9lPSEQvF2= NGnsSWY4OiCq NUTiO4NxcW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfUBkd22kaX7l[EB4cXSqII\hcoRmfGGwaXK= MnP3NlIzPTh2N{[=
A549  MojJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVO1JO69VQ>? NIDZWGo4OiCq M{LoRolvcGmkaYTzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bImgZ49u[mmwZXSge4l1cCC4YX7k[ZRidmmk MW[yNlI2QDR5Nh?=
MCF-7 M1vSW2Z2dmO2aX;uJGF{e2G7 NXn3ZVBvOcLizszN NH\WfYgzPCCqwrC= MlG1[I94dnKnZ4XsZZRmeyCHUjDlfJBz\XO|aX;uJIlv\HWlZXSgZpkhPC2RSD3UJOKh NGjvUpczOjB2OUOxOi=>
HCC-1428 M3\nSmZ2dmO2aX;uJGF{e2G7 MnvYNeKh|ryP NG\ObWozPCCqwrC= MWrkc5dvemWpdXzheIV{KEWUIHX4dJJme3Orb36gbY5lfWOnZDDifUA1NU:KLWSgxsA> M1\sXVIzODR7M{G2
MDA-361 M1jzVWZ2dmO2aX;uJGF{e2G7 NUT3UJZLOcLizszN NIrQRoczPCCqwrC= NXzYXW01\G:5boLl[5Vt[XSnczDFVkBmgHC{ZYPzbY9vKGmwZIXj[YQh[nliND3PTE1VKMLi NUn2PXJvOjJyNEmzNVY>
ZR75-1 NXPiXlJmTnWwY4Tpc44hSXO|YYm= MojNNeKh|ryP M{XmPFI1KGkEoB?= Mnnt[I94dnKnZ4XsZZRmeyCHUjDlfJBz\XO|aX;uJIlv\HWlZXSgZpkhPC2RSD3UJOKh NXLqfpBVOjJyNEmzNVY>
MCF-7 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHCNeKh|ryP MUS1MVExKGR? MUXzeZBxemW|c3XzJGUzNWmwZIXj[YQh\3Kxd4ToJIlvcGmkaYTpc44> NYnUdItqOjJyNEmzNVY>
HCC-1428 NXTPWlNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHqNeKh|ryP NWP4NmRbPS1zMDDk M3HKbJN2eHC{ZYPz[ZMhTTJvaX7keYNm\CCpcn;3eIghcW6qaXLpeIlwdg>? NH\xUpYzOjB2OUOxOi=>
MDA-361 NUi3WWM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWmzZ49EOcLizszN NYXld4JpPS1zMDDk MnPxd5VxeHKnc4Pld{BGOi2rbnT1Z4VlKGe{b4f0bEBqdmirYnn0bY9v MorQNlIxPDl|MU[=
ZR75-1 NVLOTINGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGr4Z2QyyqEQvF2= NHzxeVI2NTFyIHS= NXHucWoxe3WycILld5NmeyCHMj3pcoR2[2WmIHfyc5d1cCCrbnjpZol1cW:w NWfvO2tCOjJyNEmzNVY>
MCF-7/AC-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvUNE0xNjJizszN MW[2JIQ> MVTpcohq[mm2czDj[YxtKGe{b4f0bEBud2Snc4TsfS=> NWe1WJd3OjJyNEK3PVI>
MCF7 M{jmbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3OzZ|ExKML3TR?= M3u4bFQ5KGh? NVTNS|JGcW6mdXPld{Bk\WyuIHnubIljcXSrb36ge4hq[2hiY3HuJIJmKGWwaHHuZ4VlKGK7IH\pZpJw[myjc4Tz NXHuW41nOjJyNEG4PFc>
MMQ MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M16x[|AuPjJ3IH7N MV[3NkBp MVPwdo9lfWOnczDzeIF1cXO2aXPhcIx6KHOrZ37p[olk[W62IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vyqB? MWOyNlAyPTFyMR?=
MMQ Mly5SpVv[3Srb36gRZN{[Xl? M3KwVFAuPjJ3IH7N NFPG[IY4OiCq MmXmdJJw\HWlZYOgZUB{fGG2aYP0bYNidGy7IIPp[45q\mmlYX70MEBld3OnLXTldIVv\GWwdDDy[YR2[3Srb36gbY4hWFKOIIPlZ5JmfGmxbh?= M2PsbFIzODF3MUCx
MCF7 NXHqeZY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjFRWhiOC1zIN88US=> Ml7TNlQuOTJyIHi= M4H4ZolvcGmkaYTzJJRp\SCpcn;3eIghd2ZiTVPGO{1[Si1zwrC= NFvnU5QzOTh4M{K1PC=>
HepG2 M2m5V2Fxd3C2b4Ppd{BCe3OjeR?= NUXHVHpQOC5zwrFOwG0> NF65OHIzPCCq M4XZO4Fjd2yrc3jld{B1cGViZYP0do9o\W5vaX7keYNm\CC3cD3y[Yd2dGG2aX;uJI9nKGGyb1HJJIFv\CCjcH;N MnLQNlE5OTZ{M{O=
MCF7–iFR3 NWLPTnZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXiyNE0yODBibl2= MofiPVYhcA>? Mkju[Y5p[W6lZYOgRXAucW6mdXPl[EBk\WyuIHfyc5d1cCCrbnjpZol1cW:w NI\EW|UzOTd7Mki4PS=>
MCF7S MYLGeY5kfGmxbjDBd5NigQ>? MXuxxsDPxE1? MVe0PEBp NXLIdmli\G:5boLl[5Vt[XSnczDveoVz[WyuIFXS{tEheHKxdHXpckBt\X[nbIO= MmntNlE2OzNzOUW=
MCF7 NXPhOYloTnWwY4Tpc44hSXO|YYm= MlfCNeKh|ryP NGOy[Hg1QCCq NWD6cGVE\G:5boLl[5Vt[XSnczDveoVz[WyuIFXS{tEheHKxdHXpckBt\X[nbIO= NH74UGczOTV|M{G5OS=>
MCF7S NHuwZ3pHfW6ldHnvckBCe3OjeR?= Mo[4NeKh|ryP M3f5fVch\A>? NV;3WJZI[XS2ZX71ZZRmeyC2dX3vdpNxcGW{ZTDmc5Ju[XSrb36gZY5lKHC{b3zp[oVz[XSrb36= MljtNlE2OzNzOUW=
MCF7S M{frd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY[wMlUwOSEQvF2= MYO3JIQ> MWHEUXNQ MoX2[IVkemWjc3XzJINmdGxiZYjwZY5{cW:w NYPRbVNFOjF3M{OxPVU>
T47D  NGjjNW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7jV25lPCCwTR?= M3TONlQxKGh? NELwOmd{fXCycnXzd4V{KGOnbHyg[5Jwf3SqIH3v[IVz[XSnbIm= MoLRNlE1QDB|OUG=
BT474  NFji[YNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\TOEBvVQ>? NUHBfnJ3PDBiaB?= NIXjemx{fXCycnXzd4V{KGOnbHyg[5Jwf3SqIH3v[IVz[XSnbIm= NEjzfI4zOTR6MEO5NS=>
T47D  NGDOT3dHfW6ldHnvckBCe3OjeR?= NUPPeWNzOTBibl2= MXq0NEBp M1[4OoRwf26{ZXf1cIF1\XNiRWNOtUBxem:2ZXnu MnPxNlE1QDB|OUG=
BT474  MkLBSpVv[3Srb36gRZN{[Xl? MYmxNEBvVQ>? MkfsOFAhcA>? MV;kc5dvemWpdXzheIV{KEWUzsGgdJJwfGWrbh?= MXGyNVQ5ODN7MR?=
MCF7 M2nldWZ2dmO2aX;uJGF{e2G7 MVSxNFAhdk1? MluxO{Bl MXXy[YR2[2W|IFXS{tEh\XiycnXzd4lwdiC|aXfubYZq[2GwdHz5 NEXtOo8zOTN7NkC5OC=>
T47D  MnXlSpVv[3Srb36gRZN{[Xl? NHTKb5AyODBibl2= M2HtXlch\A>? NIrLPYFz\WS3Y3XzJGVT|rFiZYjwdoV{e2mxbjDzbYdvcW[rY3HueIx6 MUeyNVM6PjB7NB?=
BT474  NH\ucHJHfW6ldHnvckBCe3OjeR?= M1zJVVExOCCwTR?= MUi3JIQ> NXG4[3VSemWmdXPld{BGWs7zIHX4dJJme3Orb36gd4lodmmoaXPhcpRtgQ>? NVi3d|hPOjF|OU[wPVQ>
MDAMB361 NEPIPZpHfW6ldHnvckBCe3OjeR?= NXPWUpVIOTByIH7N NXzWepAyPyCm MWTy[YR2[2W|IFXS{tEh\XiycnXzd4lwdiC|aXfubYZq[2GwdHz5 Mmr4NlE{QTZyOUS=
MCF7 M3;CSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjpR|RvOC5yMT2xJO69VQ>? M4XKU|ch\A>? M4XNXJJm\HWlZYOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueR?= NF3EUHYzOTN7NkC5OC=>
T47D  NWD6S2ZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\qWXkxNjBzLUGg{txO MVW3JIQ> NEL6fIhz\WS3Y3XzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bIm= M{P2Z|IyOzl4MEm0
BT474  M1mweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MontNE4xOS1zIN88US=> MVy3JIQ> M{HSUpJm\HWlZYOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueR?= M3u0eVIyOzl4MEm0
MDAMB361 NUW4VVRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LqT|AvODFvMTFOwG0> MoO0O{Bl MmrQdoVlfWOnczDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7 MWiyNVM6PjB7NB?=
MCF7 Mk\QSpVv[3Srb36gRZN{[Xl? NWHBVZJzOTByIH7N M4r6d|ch\A>? M{HnbYlv\HWlZYOgc4YhTXKkQkOgZY5lKEW{YlK0JJJm[2WydH;yJIV5eHKnc4Ppc44h[W6mIIPp[45idGyrbne= NYXafGJ1OjF|OU[wPVQ>
T47D  NF;acmZHfW6ldHnvckBCe3OjeR?= NXrnOJd5OTByIH7N NIr1SIY4KGR? M3HFbolv\HWlZYOgc4YhTXKkQkOgZY5lKEW{YlK0JJJm[2WydH;yJIV5eHKnc4Ppc44h[W6mIIPp[45idGyrbne= MknYNlE{QTZyOUS=
BT474  M1j2Z2Z2dmO2aX;uJGF{e2G7 MXixNFAhdk1? NXiwSYsxPyCm MlHJbY5lfWOnczDv[kBGemKEMzDhcoQhTXKkQkSgdoVk\XC2b4Kg[ZhxemW|c3nvckBidmRic3nncoFtdGmwZx?= MWqyNVM6PjB7NB?=
MDAMB361 MVLGeY5kfGmxbjDBd5NigQ>? NH7KUmIyODBibl2= NGT6Xoo4KGR? NULiVXRTcW6mdXPld{Bw\iCHcnLCN{BidmRiRYLiRlQhemWlZYD0c5Ih\XiycnXzd4lwdiCjbnSgd4lodmGubHnu[y=> Ml7RNlE{QTZyOUS=
MCF7 MmPNSpVv[3Srb36gRZN{[Xl? MWqxNEBvVQ>? MXe5OkBp NFi4e5hld3ewcnXneYxifGW|IFXSJIV5eHKnc4Ppc47DqA>? M3LkflIyOzd6M{Oz
MDA-MB-231 M1XLc2Z2dmO2aX;uJGF{e2G7 MVKxNEBvVQ>? MYK5OkBp M3OzcIRwf26{ZXf1cIF1\XNiRWKg[ZhxemW|c3nvcuKh MmrVNlE{Pzh|M{O=
SK-BR-3 MknDSpVv[3Srb36gRZN{[Xl? NIrCV4kyOCCwTR?= MWK5OkBp MXHkc5dvemWpdXzheIV{KEWUIHX4dJJme3Orb39CpC=> NH7qVoQzOTN5OEOzNy=>
MCF-7 M2DRd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPrO5VEOTByIH7N NFfCTVc4Oi97NjDo M4r6foNifXOnczDj[YxtKGO7Y3zlJIFzemW|dB?= M3PybVIyOjl7OE[y
MMQ NEXxUoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUL0eFJOOC5yMEitOlI2KG6P NI\FbmY4OiCq NYToPHpvcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NX\GR41YOjB5MEC3OVU>
MMQ NWHHRolHTnWwY4Tpc44hSXO|YYm= MojoNE4xODhvNkK1JI5O M4jGbFczKGh? NITsV4NqdmirYnn0d{BRWkxic3XjdoV1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MX2yNFcxODd3NR?=
MMQ MV;GeY5kfGmxbjDBd5NigQ>? MWiwMlA1NTZ{NTDuUS=> MYm3NkBp NYXlR|lEcW6qaXLpeJMhTVMQsTDlfJBz\XO|aX;u NVm3fVloOjB5MEC3OVU>
MMQ MorqSpVv[3Srb36gRZN{[Xl? MojZNE4xPC14MkWgcm0> NGfXNYs4OiCq NIrET4J2eHKnZ4XsZZRmeyCWR1dOtlMh[W6mIGTHSu6zWkmLIHX4dJJme3Orb36= NULy[XpvOjB5MEC3OVU>

... Click to View More Cell Line Experimental Data

In vivo Fulvestrant is devoid of uterotropic activity, and when co-administered with estradiol, it effectively blocks the uterotropic action of estradiol with ED50 of 0.06 mg/kg/day s.c. in immature female rats. A single s.c. injection of 5 mg of Fulvestrant suspension blocks completely the growth of MCF-7 xenografts. The growth of transplants of the BrlO human breast tumor is also suppressed effectively by 10 μM Fulvestrant. [1] Fulvestrant (10 mg/rat, s.c.) reduces the androgen receptor expression, ERK1/2 phosphorylation and cell proliferation in the rat ventral prostate. [7] Fulvestrant also displays anti-angiogenesis in the chick egg chorioallantoic membrane. [8]

Protocol

Cell Research
+ Expand
  • Cell lines: MCF-7 breast cancer cells
  • Concentrations: 2.9 nM
  • Incubation Time: 5 days
  • Method: MCF-7 cells are cultured in multiwell plates (24-well, seeding density 4 × 104) in minimal essential medium containing phenol red, insulin (10 μg/mL), and 5% charcoal-stripped fetal calf serum without additional estradiol. Fulvestrant and/or estradiol are added in fresh medium 2 days after seeding. Cultures are maintained for 5 days with one further medium change and growth is assessed by measurement of total cell protein at the beginning and end of treatment and compared with that of controls treated with ethanol (0.1%) alone.
    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: The human breast cancer xenografts MCF-7 in nude mice
  • Formulation: 50 mg/mL in arachis oil
  • Dosages: 5 mg/mouse
  • Administration: s.c. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (164.8 mM)
Ethanol 100 mg/mL warmed (164.8 mM)
Water <1 mg/mL
In vivo 5% DMSO+95% Corn oil 30mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 606.77
Formula

C32H47F5O3S

CAS No. 129453-61-8
Storage powder
in solvent
Synonyms ICI-182780, ZD 9238

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02763566 Not yet recruiting Breast Cancer Eli Lilly and Company October 2016 Phase 3
NCT02476786 Not yet recruiting Breast Cancer|Cancer of Breast|Breast Neoplasms|Cancer of the Breast Washington University School of Medicine|Genomic Health®, Inc. October 2016 Phase 2
NCT02738866 Not yet recruiting Metastatic Breast Cancer Sidney Kimmel Comprehensive Cancer Center|Pfizer July 2016 Phase 2
NCT02795039 Active, not recruiting Healthy Fresenius Kabi June 2016 Phase 1
NCT02756364 Not yet recruiting Breast Neoplasms Millennium Pharmaceuticals, Inc. June 2016 Phase 2
NCT02684032 Recruiting Breast Cancer Pfizer June 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is there any information for the half-life of fulvestrant (Cat No.S1191)?

  • Answer:

    S1191, is about 13.5 to 18.5 hours in vivo: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750771/. The half life of these compounds in cell culture might be different and we generally recommend replenishing with fresh drug every 24-48 hours.

Estrogen/progestogen Receptor Signaling Pathway Map

Estrogen/progestogen Receptor Inhibitors with Unique Features

Related Estrogen/progestogen Receptor Products

Tags: buy Fulvestrant | Fulvestrant ic50 | Fulvestrant price | Fulvestrant cost | Fulvestrant solubility dmso | Fulvestrant purchase | Fulvestrant manufacturer | Fulvestrant research buy | Fulvestrant order | Fulvestrant mouse | Fulvestrant chemical structure | Fulvestrant mw | Fulvestrant molecular weight | Fulvestrant datasheet | Fulvestrant supplier | Fulvestrant in vitro | Fulvestrant cell line | Fulvestrant concentration | Fulvestrant nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID